Aprea Therapeutics Inc APRE.OQ APRE.O is expected to show a rise in quarterly revenue when it reports results on March 24 (estimated) for the period ending December 31 2024
The Doylestown Pennsylvania-based company is expected to report a 1,090.5% increase in revenue to $166.67 thousand from $14 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Aprea Therapeutics Inc is for a loss of 69 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aprea Therapeutics Inc is $16.00, above its last closing price of $2.42.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.68 | -0.74 | -0.64 | Beat | 14.1 |
Jun. 30 2024 | -0.61 | -0.63 | -0.58 | Beat | 8.7 |
Mar. 31 2024 | -0.79 | -0.78 | -0.67 | Beat | 13.7 |
Dec. 31 2023 | -0.77 | -0.92 | Missed | -19 | |
Sep. 30 2023 | -1.16 | -1.16 | -0.86 | Beat | 26.1 |
Jun. 30 2023 | -1.42 | -1.42 | -0.87 | Beat | 38.9 |
Mar. 31 2023 | -1.52 | -1.50 | -1.34 | Beat | 11 |
Dec. 31 2022 | -4.04 | -3.08 | -0.92 | Beat | 70.1 |
This summary was machine generated March 21 at 12:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。